Articles related to DYSLIPIDEMIA

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

Double-filtration plasmapheresis reduced circulating concentrations of several PFAS in small patient samples, while microplastic changes varied by polymer. The exploratory findings do not support apheresis for environmental pollutant removal.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.

Discontinuing statins in adults 75 years and older without prior cardiovascular disease did not increase mortality or major cardiovascular events over three years in a randomized trial. LDL cholesterol rose substantially after discontinuation, and longer-term effects remain uncertain.

The 2026 ACC/AHA dyslipidemia guideline reintroduces LDL-C treatment targets, expands risk assessment, and recommends universal Lp(a) screening. New analyses suggest many US adults now exceed recommended cholesterol thresholds, although treatment decisions remain individualized.

A post-thyroidectomy patient’s LDL-C rose above 250 mg/dL during recurrent hypothyroidism and improved after euthyroidism returned. The case highlights medication adherence and secondary-cause review before lipid-therapy escalation.